NELL-1, HMGB1, and CCN2 Enhance Migration and Vasculogenesis, But Not Osteogenic Differentiation Compared to BMP2

• Published in: Tissue engineering. Part A Vol. 24; no. 3-4; pp. 27 - 218
• Main Authors: Fahmy-Garcia, Shorouk, van Driel, Marjolein, Witte-Buoma, Janneke, Walles, Heike, van Leeuwen, Johannes P.T.M., van Osch, Gerjo J.V.M, Farrell, Eric
• Format: Journal Article
• Language: English
• Published: United States Mary Ann Liebert, Inc., publishers 01.02.2018; Mary Ann Liebert, Inc
• Subjects: Angiogenesis; Autografts; Biomedical materials; Bone biomaterials; Bone growth; Bone healing; Bone morphogenetic protein 2; Bone Morphogenetic Protein 2 - genetics; Bone Morphogenetic Protein 2 - metabolism; Cell adhesion & migration; Cell differentiation; Cell Differentiation - genetics; Cell Differentiation - physiology; Cell migration; Cell Movement - genetics; Cell Movement - physiology; Cells, Cultured; Child; Connective tissue growth factor; Connective Tissue Growth Factor - genetics; Connective Tissue Growth Factor - metabolism; Defects; Drug dosages; Endothelial cells; Female; Growth factors; HMGB1 protein; HMGB1 Protein - genetics; HMGB1 Protein - metabolism; Human Umbilical Vein Endothelial Cells; Humans; Internal medicine; Male; Maxillofacial surgery; Medicine; Mesenchymal Stem Cells - metabolism; Mesenchymal Stem Cells - physiology; Mesenchyme; Mineralization; Morbidity; Nerve Tissue Proteins - genetics; Nerve Tissue Proteins - metabolism; Original Articles; Osteogenesis; Osteogenesis - genetics; Osteogenesis - physiology; Otolaryngology; Pain; Proteins; Rodents; Stem cells; Stromal cells; Studies; Surgery; Tissue engineering; Vascular endothelial growth factor; Vascularization; Netherlands; NELL-1; BMP2; vascularization; HMGB1; osteogenesis; CCN2/CTGF
• ISSN: 1937-3341; 1937-335X
• DOI: 10.1089/ten.tea.2016.0537

Currently, autografts still represent the gold standard treatment for the repair of large bone defects. However, these are associated with donor-site morbidity and increased pain, cost, and recovery time. The ideal therapy would use biomaterials combined with bone growth factors to induce and instruct bone defect repair without the need to harvest patient tissue. In this line, bone morphogenetic proteins (BMPs) have been the most extensively used agents for clinical bone repair, but at supraphysiological doses that are not without risk. Because of the need to eliminate the risks of BMP2 use in vivo , we assessed the ability of three putative osteogenic factors, nel-like molecule type 1 (NELL-1), high mobility group box 1 (HMGB1), and CCN2, to enhance the essential processes for bone defect repair in vitro and compared them to BMP2. Although it has been reported that NELL-1, HMGB1, and CCN2 play a role in bone formation, less is known about the contribution of these proteins to the different events involved, such as cell migration, osteogenesis, and vasculogenesis. In this study, we investigated the effects of different doses of NELL-1, HMGB, CCN2, and BMP2 on these three processes as a model for the recruitment and differentiation of resident cells in the in vivo bone defect repair situation, using cells of human origin. Our data demonstrated that NELL-1, HMGB1, and CCN2 significantly induced mesenchymal stem cell migration (from 1.58-fold increase compared to control), but BMP2 did not. Interestingly, only BMP2 increased osteogenesis in marrow stromal cells, whereas it inhibited osteogenesis in preosteoblasts. Moreover, the four proteins studied promoted significantly endothelial cell migration, reaching a maximum of 2.4-fold increase compared to control, and induced formation of tube-like structures. NELL-1, HMGB1, and CCN2 had these effects at relatively low doses compared to BMP2. This work indicates that NELL-1, HMGB1, and CCN2 might enhance bone defect healing via the recruitment of endogenous cells and induction of vascularization and act via different processes than BMP2.